News | December 06, 2006

Longer Use of Clopidogrel Explored

Taking anti-platelet medication longer than current recommendations may lower heart attack or death risks for patients with drug-eluting stents, according to a study funded by the Agency for Healthcare Research and Quality and published this week in the online version of JAMA.

Clopidogrel is currently recommended for three to six months after placement of DES. But the new observational study by AHRQ's DEcIDE Research Center at Duke University suggests the drug reduces risks of heart attack or death for at least two years in some patients, Newswire reports.

"This study suggests that patients and their physicians should consider extending the period of use of this therapy while monitoring its effects very carefully,'' said AHRQ Director Carolyn M. Clancy, MD. "Further research will help us understand fully the balance of risks and benefits of extended use of anti- platelet therapy in people who have drug-eluting stents."

How long clopidogrel may be needed, however, remains uncertain.

The Duke study included 4,666 patients who received drug-eluting stents or bare metal stents during a five-year period. Of those, 3,609 were defined as "event free,'' meaning they had not died, had heart attacks or undergone additional procedures to open coronary arteries for at least six months since stent placement. Researchers then checked those patients' use of clopidogrel and their health status through September 2006. The study concluded:

-- Among drug-eluting stent patients who were event free at six months, those who reported clopidogrel use were significantly less likely to die during the next 18 months than those who did not use the drug (a 2 percent death rate vs. a 5.3 percent death rate). These patients were also less likely to either die or have a heart attack (3.1 percent vs. 7.2 percent).

-- Among patients who had been event free for a full year, those who reported clopidogrel use at 12 months were similarly less likely than those not taking clopidogrel to die during the next 12 months (0 percent vs. 3.5 percent), and less likely to either die or have a heart attack (0 percent vs. 4.5 percent).

For more information about DEcIDE and the EHC program, visit http://www.effectivehealthcare.ahrq.gov.

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init